Progress in preventing chemotherapy-induced nausea and vomiting

Cleveland Clinic Journal of Medicine

Volumn 69, Issue 8, 2002, Pages 609-617

  Markman, Maurie ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CANNABINOID; CARBOPLATIN; CARMUSTINE; CHLORPROMAZINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; DRONABINOL; DROPERIDOL; EPIRUBICIN; GRANISETRON; HALOPERIDOL; IFOSFAMIDE; LORAZEPAM; MEPREDNISONE; METOCLOPRAMIDE; MITOXANTRONE; NEUROTRANSMITTER; ONDANSETRON; PROCHLORPERAZINE; SEROTONIN ANTAGONIST; UNINDEXED DRUG;

AGITATION; ARTICLE; ATAXIA; CARDIOTOXICITY; CONSTIPATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG MECHANISM; DRUG POTENTIATION; DYSTONIA; HEADACHE; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; RISK FACTOR; SEDATION; SLEEP DISORDER; VERTIGO;

EID: 0036685084     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.8.609     Document Type: Article

References (34)

1. Neuropharmacology of chemotherapy induced emesis
2. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference
3. A proposal for classifying the acute emetogenicity of cancer chemotherapy
4. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines
5. Metoclopramide: Dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy
6. Extrapyramidal reactions with high-dose metoclopramide
7. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion
8. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin
9. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients
10. Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: Prevalence, etiology, and behavioral interventions
11. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting
12. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting
13. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin
14. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer
15. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis
16. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study
17. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis
18. Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone
19. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer
20. Control of chemotherapy-induced emesis
21. Antiemetic efficacy of dexamethasone: Randomized double-blind crossover study of prochlorperazine in patients receiving cancer chemotherapy
22. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis
23. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind cross-over study
24. Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting
25. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy
26. Antiemetic therapy: A review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol
27. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine used in combination with metoclopramide plus dexamethasone: A double-blind, randomized trial
28. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy
29. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis
30. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy
31. Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin
32. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy
33. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis
34. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist